Governance Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/07/2025 BST			5-day change	1st Jan Change
18.31 ^USD	-2.92%		+9.05%	-2.61%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Executive Committee: Arrowhead Pharmaceuticals, Inc.

Manager

Positions heldSince

Christopher Anzalone

55 year

Chief Executive Officer	30/11/2007
President	30/11/2007

Bruce Given

70 year

Chief Tech/Sci/R&D Officer

31/01/2024

Aaron Tan

Comptroller/Controller/Auditor

30/06/2021

Nadia Meshkova

Treasurer

Peter Carignan

Chief Tech/Sci/R&D Officer

31/07/2022

Randy Steiner

General Counsel

31/03/2020

Patrick O'brien

61 year

Compliance Officer	30/11/2014
Chief Operating Officer	14/07/2022
General Counsel	30/11/2014
Corporate Secretary	30/11/2014

Vincent Anzalone

Investor Relations Contact

Daniel J. Apel

Director of Finance/CFO

12/05/2025

Composition of the Board of Directors: Arrowhead Pharmaceuticals, Inc.

Director

CommitteesSince

William Waddill

68 year

Compensation Committee	14/04/2024
Audit Committee Chair	14/04/2024
Nominating Committee
Governance Committee

Hong Bo Lu

54 year

Governance Committee	31/10/2022
Nominating Committee	31/10/2022
Compensation Committee

Mauro Ferrari

65 year

Audit Committee	22/08/2010
Nominating Committee	04/02/2013

Michael Perry

65 year

Nominating Committee	01/01/2012
Compensation Committee Chair	01/01/2012

Adeoye Olukotun

80 year

Compensation Committee	04/09/2018
Nominating Committee	31/08/2020

Victoria Vakiener

61 year

Audit Committee
Nominating Committee Chair

Douglas Ingram

62 year

Compensation Committee Chair

31/05/2019

Christopher Anzalone

55 year

Director/Board Member

30/11/2007

Latest Appointments: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer	04-15	MT
Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO	04-15	RE
Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director	02-07	CI
Genelux Names Matthew Pulisic as CFO	02-03	MT
Arrowhead Pharmaceuticals, Inc. Announces Retirement of Douglass Given as Director, Effective December 31, 2024	12-18	CI
Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors	11-26	CI
Carisma Therapeutics Announces Changes to Its Board of Directors	30/10/24	CI

More news

Former Officers and Directors: Arrowhead Pharmaceuticals, Inc.

Insider

Positions held

SinceUntil

Kenneth Myszkowski

Director of Finance/CFO

31/12/2008

12/05/2025

Matt Pulisic

Corporate Officer/Principal

31/07/2020

30/01/2025

Douglass Given

Director/Board Member	22/11/2010	07/01/2013
Chairman	07/01/2013	30/12/2024

Javier San Martin

Chief Tech/Sci/R&D Officer

17/11/2019

31/01/2024

Marianne de Backer

Director/Board Member	11/12/2019	01/04/2023
Independent Dir/Board Member	11/12/2019	01/04/2023

Jane Davidson

Chief Administrative Officer	08/02/2012	-
Chief Operating Officer	31/01/2004	08/02/2012
Human Resources Officer	07/01/2013	30/11/2022
Corporate Secretary	07/01/2013	-

Tracie Oliver

Corporate Officer/Principal

31/05/2022

James Hassard

Corporate Officer/Principal

05/01/2020

22/08/2021

Sohanya Cheng

Sales & Marketing

31/07/2020

30/11/2020

Curt Bradshaw

Chief Tech/Sci/R&D Officer

17/11/2019

31/10/2020

Jeff Ketelhut

Chief Tech/Sci/R&D Officer

29/02/2020

Zhen Li

Corporate Officer/Principal

01/04/2014

27/01/2019

Peter B. Leone

Corporate Officer/Principal

31/03/2012

06/01/2019

Roger Kornberg

Director/Board Member

04/06/2017

Steven Kanner

Corporate Officer/Principal

18/09/2013

31/05/2017

David Lewis

Chief Tech/Sci/R&D Officer	18/09/2013	12/12/2016
Corporate Officer/Principal	19/12/2011	18/09/2013

Charles P. McKenney

Director/Board Member	31/03/2004	26/08/2015
Independent Dir/Board Member	31/03/2004	26/08/2015

Susan Boynton

Compliance Officer	-	-
General Counsel	29/09/2014	-
Corporate Officer/Principal	-	-

David Rozema

Corporate Officer/Principal

19/12/2011

Brendan P. Rae

Corporate Officer/Principal

31/10/2011

Mark G. Tilley

Corporate Officer/Principal

30/04/2008

31/01/2011

Lee T. Rahn

Director/Board Member

31/12/2003

18/08/2010

Thomas N. Haag

General Counsel

31/03/2008

29/09/2009

Paul Clayton McDonnel

Comptroller/Controller/Auditor	31/12/2005	08/08/2009
Director of Finance/CFO	31/12/2005	08/08/2009

Larry Stambaugh

President

21/02/2008

Joseph Theodore Kingsley

Director of Finance/CFO	-	13/01/2008
Corporate Secretary	-	13/01/2008
Director of Finance/CFO	10/08/2009	02/02/2010

John George Petrovich

Corporate Officer/Principal

31/12/1999

30/10/2007

Leon Ekchian

President

13/11/2005

01/06/2006

John C. Miller

Corporate Officer/Principal

30/04/2004

Edward W. Frykman

Director/Board Member	31/12/2003	-
Independent Dir/Board Member	31/12/2003	-

Robert Bruce Stewart

Chairman	31/12/2003	-
Founder	31/12/1988	-

Thomas Schluep

Corporate Officer/Principal

Howard Lovy

Public Communications Contact

Marshall Robert Ching

Corporate Officer/Principal

Charles Patrick Collier

Director/Board Member

Chad Mirkin

Corporate Officer/Principal

Virginia E. Dadey

Public Communications Contact

Caroline LaPlaca Davis

Chief Tech/Sci/R&D Officer

James M. Phillips

Corporate Secretary

Age distribution of managers

Parity Men Women

Male	15
Female	2

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	7
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

BBB

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

609

Sector

Biotechnology & Medical Research

Calendar

08-10 - Q3 2025 Earnings Release (Projected)

More about the company